The MYC network: Hub of malignancy and blueprint for intervention

MYC family transcription factors are central regulators of cell growth, proliferation, metabolism, differentiation, and apoptosis, and their dysregulation contributes to many human cancers. c-Myc, N-Myc, and L-Myc share a conserved basic helix-loop-helix leucine zipper domain that mediates MAX dimerization and DNA binding, yet they differ in tissue distribution, developmental roles, modes of activation, and tumor-type associations. In this review, we synthesize current knowledge of the MYC oncogenic network, with emphasis on upstream activation mechanisms, post-translational regulation, transcriptional outputs, structural features relevant to drug discovery, and emerging therapeutic strategies. We discuss how c-Myc and N-Myc integrate oncogenic signaling with chromatin regulation, lineage plasticity, metabolic rewiring, immune modulation, and therapy resistance in a context-dependent manner. We also summarize the therapeutic landscape, including direct disruption of MYC-MAX interactions, stabilization of MAX homodimers, interference with DNA binding, inhibition of transcriptional and epigenetic dependencies, modulation of MYC protein stability, targeted degradation approaches, metabolic interventions, and emerging strategies against extrachromosomal DNA-driven MYC amplification. Recent clinical progress with Omomyc-derived OMO-103 and other MYC-network-targeting agents supports the feasibility of therapeutically intercepting this historically challenging pathway. However, because many MYC-directed strategies affect essential transcriptional, chromatin, and metabolic programs, future development will require careful biomarker selection, rational combinations, and rigorous evaluation of therapeutic windows. By integrating mechanistic and translational literature, this review highlights MYC as a dynamic cancer dependency and discusses opportunities for precision intervention.